Absci Corporation (ABSI) |
|
1.66 -0.04 (-2.35%)
|
06-09 14:14 |
|
Open: |
1.74 |
Pre. Close: |
1.7 |
|
High:
|
1.78 |
Low:
|
1.61 |
|
Volume:
|
248,962 |
Market Cap:
|
154(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 1:43:04 PM |
|
Short-term rate:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.39 One year: 2.79 |
| Support: |
Support1: 1.48 Support2: 1.12 |
| Resistance: |
Resistance1: 2.04 Resistance2: 2.39 |
| Pivot: |
1.74  |
| Moving Average: |
MA(5): 1.75 MA(20): 1.61
MA(100): 2 MA(250): 2.71 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 63.8 %D(3): 68.3 |
| RSI: |
RSI(14): 51.2 |
| 52-week: |
High: 7.03 Low: 1.12 |
| Average Vol(K): |
3-Month: 487 (K) 10-Days: 625 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABSI ] has closed above bottom band by 36.3%. Bollinger Bands are 29.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.82 - 1.83 |
1.83 - 1.84 |
|
Low:
|
1.62 - 1.63 |
1.63 - 1.64 |
|
Close:
|
1.68 - 1.7 |
1.7 - 1.71 |
|
Company Description |
|
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington. |
Headline News |
Wed, 07 Jun 2023
Director at Absci Acquires Company Stock Options Worth 106,200 Shares - Absci (NASDAQ:ABSI) - Benzinga
Wed, 07 Jun 2023
Shareholders in Absci (NASDAQ:ABSI) are in the red if they invested a year ago - Yahoo Eurosport UK
Wed, 07 Jun 2023
Absci Corporation (ABSI) Moving Averages: 50-Day and 200-Day - The Dwinnex
Tue, 06 Jun 2023
2023-06-06 | NDAQ:ABSI | Press Release | Absci Corporation - Stockhouse Publishing
Tue, 30 May 2023
What is Wall Street's Target Price for Absci Corp (ABSI) Stock Tuesday? - InvestorsObserver
Tue, 30 May 2023
Healthcare Stocks on the Move Tuesday: AVAH, MNPR, TARO, ABSI, TCRX, BHG, ENVB, AVIR - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
93 (M) |
|
% Held by Insiders
|
5.498e+007 (%) |
|
% Held by Institutions
|
32 (%) |
|
Shares Short
|
4,360 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-8.805e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
640.8 |
|
Return on Equity (ttm)
|
-18.4 |
|
Qtrly Rev. Growth
|
6.2e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-1.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-80 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
4.22e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
